{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T18:46:44Z","timestamp":1768070804010,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4051-0","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T08:28:51Z","timestamp":1517905731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data"],"prefix":"10.1186","volume":"18","author":[{"given":"Qiufei","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shilkrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Batty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"4051_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2015. \n                    http:\/\/www.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-044552.pdf\n                    \n                  . Accessed Jan 2016."},{"key":"4051_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejca.2009.10.032","volume":"46","author":"C Garbe","year":"2010","unstructured":"Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer Oxf Engl. 2010;46:270\u201383.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"4051_CR3","unstructured":"National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae); Melanoma Version 2.2016."},{"key":"4051_CR4","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"4051_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1185\/03007995.2015.1021904","volume":"31","author":"X Song","year":"2015","unstructured":"Song X, Zhao Z, Barber B, Farr AM, Ivanov B, Novich M. Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 2015;31:987\u201391.","journal-title":"Curr Med Res Opin"},{"issue":"7 Pt 2","key":"4051_CR6","doi-asserted-by":"publisher","first-page":"2353s","DOI":"10.1158\/1078-0432.CCR-05-2503","volume":"12","author":"MB Atkins","year":"2006","unstructured":"Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(7 Pt 2):2353s\u20138s.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"4051_CR7","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","volume":"26","author":"MB Atkins","year":"2008","unstructured":"Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (e3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol. 2008;26:5748\u201354.","journal-title":"J Clin Oncol"},{"key":"4051_CR8","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1200\/JCO.1997.15.7.2579","volume":"15","author":"U Keilholz","year":"1997","unstructured":"Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Li\u00e9nard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of cancer melanoma cooperative group. J Clin Oncol. 1997;15:2579\u201388.","journal-title":"J Clin Oncol"},{"key":"4051_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/phar.1643","volume":"35","author":"NM La-Beck","year":"2015","unstructured":"La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35:963\u201376.","journal-title":"Pharmacotherapy"},{"key":"4051_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354.","journal-title":"Nature"},{"key":"4051_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13555-015-0080-7","volume":"5","author":"L John","year":"2015","unstructured":"John L, Cowey CL. The rapid emergence of novel therapeutics in advanced malignant melanoma. Dermatol Ther. 2015;5:151\u201369.","journal-title":"Dermatol Ther"},{"key":"4051_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12180","volume":"1291","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291:1\u201313.","journal-title":"Ann N Y Acad Sci"},{"key":"4051_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fimmu.2014.00206","volume":"5","author":"Y-CM Kong","year":"2014","unstructured":"Kong Y-CM, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol. 2014;5:206.","journal-title":"Front Immunol"},{"key":"4051_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"4051_CR15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908\u201318.","journal-title":"Lancet Oncol."},{"key":"4051_CR16","unstructured":"European Medicines Agency. Ipilimumab Summary of Product Characteristics. 2011. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002213\/WC500109299.pdf\n                    \n                  . Accessed January 2015."},{"key":"4051_CR17","unstructured":"Food and Drug Administration. Ipilimumab Prescribing Information. 2015. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR18","unstructured":"European Medicines Agency. Nivolumab Summary of Product Characteristics. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003840\/WC500190648.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR19","unstructured":"Food and Drug Administration. Nivolumab Prescribing Information. 2015. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125554s005lbl.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR20","unstructured":"European Medicines Agency. Pembrolizumab Summary of Product Characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003820\/WC500190990.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR21","unstructured":"Food and Drug Administration. Pembrolizumab Prescribing Information. 2015. \n                    http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125514s005lbl.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR22","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for nivolumab. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003985\/WC500186052.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR23","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for ipilimumab. 2011. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002213\/WC500109302.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR24","unstructured":"European Medicines Agency. EPAR; Summary of the risk management plan (RMP) for pembrolizumab. 2015. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/003820\/WC500187334.pdf\n                    \n                  . Accessed January 2016."},{"key":"4051_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"4051_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"4051_CR27","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"4051_CR28","unstructured":"International Classification of Diseases, Ninth Revision, Clinical Modification - ICD-9-CM. \n                    http:\/\/www.cdc.gov\/nchs\/icd\/icd9cm.htm\n                    \n                  . Accessed January 2016."},{"key":"4051_CR29","unstructured":"American Autoimmune Related Diseases Association (AARDA) - autoimmune related disease information. \n                    http:\/\/www.aarda.org\n                    \n                  \/. Accessed January 2016."},{"key":"4051_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009;33:197\u2013207.","journal-title":"J Autoimmun"},{"key":"4051_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","volume":"29","author":"WW Eaton","year":"2007","unstructured":"Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007;29:1\u20139.","journal-title":"J Autoimmun"},{"key":"4051_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84:223\u201343.","journal-title":"Clin Immunol Immunopathol"},{"key":"4051_CR33","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.juro.2012.12.014","volume":"189","author":"X Liu","year":"2013","unstructured":"Liu X, Ji J, Forsti A, Sundquist K, Sundquist J, Hemminki K. Autoimmune disease and subsequent urological cancer. J Urol. 2013;189:2262\u20138.","journal-title":"J Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4051-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T19:15:47Z","timestamp":1549394147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4051-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4051"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4051-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"11 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used Truven MarketScan\u00ae administrative claims data. The data were de-identified and accessed in accordance with the Health Insurance Portability and Accountability Act of 1996; Institutional Review Board approval was not required for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qiufei Ma, Mark Shilkrut, Zhongyun Zhao, Nicolas Batty, and Beth Barber are currently employed by Amgen Inc. Minming Li is a PhD candidate at the University of Massachusetts, Amherst.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"145"}}